This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2022 Oct;23(10):e446.

doi: 10.1016/S1470-2045(22)00571-X.

Correction to Lancet Oncol 2022; 23: 1009-20

No authors listed

PMID: 36174629
PMCID: PMC9618325
DOI: 10.1016/S1470-2045(22)00571-X

Published Erratum

Correction to Lancet Oncol 2022; 23: 1009-20

No authors listed. Lancet Oncol. 2022 Oct.

. 2022 Oct;23(10):e446.

doi: 10.1016/S1470-2045(22)00571-X.

PMID: 36174629
PMCID: PMC9618325
DOI: 10.1016/S1470-2045(22)00571-X

No abstract available

PubMed Disclaimer

Erratum for

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, Karasic T, Tondon R, Onyiah C, Gosselin MK, Donze A, Domchek SM, Vonderheide RH. Reiss KA, et al. Lancet Oncol. 2022 Aug;23(8):1009-1020. doi: 10.1016/S1470-2045(22)00369-2. Epub 2022 Jul 7. Lancet Oncol. 2022. PMID: 35810751 Free PMC article. Clinical Trial.

Publication types

Actions

Grants and funding

P30 CA016520/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources